Rajka G, Verjans H L
J Int Med Res. 1986;14(2):85-90. doi: 10.1177/030006058601400206.
A randomized, double-blind, left-right study to compare the therapeutic efficacy and the cosmetic acceptability of the new hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream application form with desonide (Apolar) 0.1% ointment was performed in thirty patients suffering from moderate to severe atopic dermatitis. The medications were applied to symmetrical, bilateral skin lesions twice daily for 4 weeks. Both treatments effected highly significant reductions of the score values for the severity of all clinical skin parameters assessed. Score reductions were, however, more pronounced on Locoid-treated sides than on Apolar-treated sides both after 2 and 4 weeks of therapy. It appeared further that clinical efficacy of treatment at completion of the study was also in favour of Locoid-treated sides, indicating that Locoid fatty cream is more effective than Apolar ointment. No serious side-effects were reported during the study. The expressed patient preferences with respect to cosmetic acceptability of treatments were significantly in favour of Locoid fatty cream, indicating that patients preferred the use of this new galenic formulation over an ointment formulation. It is concluded that the new application form of Locoid, a fatty cream, is a useful and beneficial addition to topical corticosteroid therapy, which will promote patient compliance in a wide range of corticosteroid-responsive skin diseases.
一项随机、双盲、左右对照研究在30例中重度特应性皮炎患者中开展，比较了新型0.1%丁酸氢化可的松（乐肤液）脂肪乳膏剂型与0.1%地奈德（阿波洛）软膏的治疗效果及美容可接受性。药物每天两次涂抹于对称的双侧皮肤损害处，持续4周。两种治疗方法均使所有评估的临床皮肤参数严重程度的评分值显著降低。然而，治疗2周和4周后，乐肤液治疗侧的评分降低比阿波洛治疗侧更明显。进一步看来，研究结束时的治疗临床疗效也有利于乐肤液治疗侧，表明乐肤液脂肪乳膏比阿波洛软膏更有效。研究期间未报告严重副作用。患者对治疗美容可接受性表达的偏好明显有利于乐肤液脂肪乳膏，表明患者更喜欢使用这种新的剂型而非软膏剂型。结论是，乐肤液的新剂型脂肪乳膏是局部皮质类固醇治疗中一种有用且有益的补充，这将提高患者对多种皮质类固醇反应性皮肤病的依从性。
